Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. on February 17, 2017, covering events occurring in February 2017. The registrant is a foreign private issuer based in Kfar Saba, Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal proceeding regarding stock options and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is a court ruling regarding the company's Series-1 Stock Options:
- Initial Expiration: The Series-1 Stock Options were originally set to expire on February 15, 2017.
- First Extension: The Tel Aviv District Court previously granted interim relief extending the expiration to February 25, 2017.
- Latest Extension: On February 16, 2017, the Court granted a request for additional interim relief, extending the expiration date of the Series-1 Stock Options to June 30, 2017.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or an outlook for future periods. The document notes that this Form 6-K is incorporated by reference into the Registrant's Registration Statement on Form S-8 filed on November 28, 2016. The primary contingency addressed is the legal status of the stock options, which has been resolved in the company's favor for the short term.
Investor Verification Checklist
- Verify the terms and conditions of the Series-1 Stock Options as detailed in the Form S-8 (Registration No. 333-214817).
- Confirm whether the extension to June 30, 2017, is subject to further court hearings or conditions.
- Review the company's most recent Form 20-F for actual financial performance data, as this filing contains none.